All In Biotech

Drug Trial Radar · NCT07207070

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

May 31, 2029

Study completion May 31, 2030

Sponsor

Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • JS105Drug

    Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.

  • DalpiciclibDrug

    Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle;

  • Fulvestrant 50 Mg/mL Intramuscular SolutionDrug

    Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blind Independent Central Review (BICR) assessed PFS based on RECIST v1.1 (BICR-PFS)Time frame: Up to 3.5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chinese Acadamy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China · Recruiting

  • Henan Provincial Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.